<DOC>
	<DOCNO>NCT02496377</DOCNO>
	<brief_summary>Patients recruit scheduled preoperative visit hip knee arthroplasty . If haemoglobin ( Hb ) level 13 g/dl contraindication iron supplementation patient randomized oral intravenous ( IV ) group . The oral group receive 160 mg ferrous glycine sulfate daily month prior surgery , associate 3 epoetin alpha ( EPO ) injection ( 40 000 IU subcutaneous day - 21 , day - 14 day-7 ) . The IV group receive ferric carboxymaltose 1000 mg IV 15 minute one month surgery , associate 3 EPO injection . Primary efficacy endpoint change Hb level day preoperative visit day surgery ( day-1 ) . Secondary endpoint comprise Hb level day 3 5 surgery , allogenic transfusion surgery , change iron index day preoperative visit day - 1 .</brief_summary>
	<brief_title>Cross Iron ( Comparative Randomized Oral Versus Systemic IRON )</brief_title>
	<detailed_description />
	<mesh_term>Iron</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<criteria>Inclusion criterion : unilateral prothetic orthopaedic surgery schedule age &gt; 18 weight &gt; 50 kg hemoglobin rate : 10 g/dl â‰¤ Hb &lt; 13 g/dl Exclusion criterion : bilateral arthroplasty EPO contraindication generalize infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Anaemia</keyword>
	<keyword>Iron deficiency</keyword>
	<keyword>Ferric carboxymaltose</keyword>
	<keyword>Patient blood management</keyword>
	<keyword>Hip arthroplasty</keyword>
	<keyword>Knee arthroplasty</keyword>
</DOC>